This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baldelli, R. Articles by Tamburrano, G. Search for Related Content PubMed PubMed Citation Articles by Baldelli, R. Articles by Tamburrano, G.

Cardiac Effects of Slow-Release Lanreotide, a Slow-Release Somatostatin Analog, in Acromegalic Patients¹

Departments of Endocrinology (R.B., G.I., G.M., B.C., G.T.), Internal Medicine (C.M., R.C.), and Experimental Medicine and Pathology (A.G.), University of Rome "La Sapienza", 00161 Rome, Italy; and Department of Experimental Medicine (E.F., M.-L.J.-R.), University of L’Aquila, L’Aquila, Italy

Address all correspondence and requests for reprints to: Roberto Baldelli, M.D., Clinica Medica II - Dipartimento di Endocrinologia, Università "La Sapienza", Viale del Policlinico, 00161 Rome, Italy.

Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10–14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P < 0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P < 0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m² at baseline) decreased after 3 months (120.0 ± 5.4 g/m²), 6 months (111.7 ± 5.7 g/m²), and 12 months (110.3 ± 5.2 g/m²) of treatment (P < 0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P < 0.005 at each time-point). We conclude that SR-lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.

This article has been cited by other articles:

				P. Maison, A.-I. Tropeano, I. Macquin-Mavier, A. Giustina, and P. Chanson Impact of Somatostatin Analogs on the Heart in Acromegaly: A Metaanalysis J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1743 - 1747. [Abstract] [Full Text] [PDF]

				R. Pivonello, M. Galderisi, R. S. Auriemma, M. C. De Martino, M. Galdiero, A. Ciccarelli, A. D'Errico, I. Kourides, P. Burman, G. Lombardi, et al. Treatment with Growth Hormone Receptor Antagonist in Acromegaly: Effect on Cardiac Structure and Performance J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 476 - 482. [Abstract] [Full Text] [PDF]

				E. R. Schwarz, P. Jammula, R. Gupta, and S. Rosanio A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both? Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 232 - 244. [Abstract] [PDF]

				G. Minniti, V. Esposito, M. Piccirilli, A. Fratticci, A. Santoro, and M.-L. Jaffrain-Rea Diagnosis and management of pituitary tumours in the elderly: a review based on personal experience and evidence of literature Eur. J. Endocrinol., December 1, 2005; 153(6): 723 - 735. [Abstract] [Full Text] [PDF]

				W. H T Smith, R U. Nair, D. Adamson, M. T Kearney, S. G Ball, and A. J Balmforth Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts J. Endocrinol., December 1, 2005; 187(3): 379 - 386. [Abstract] [Full Text] [PDF]

				S W van Thiel, J J Bax, N R Biermasz, E R Holman, D Poldermans, F Roelfsema, H J Lamb, E E van der Wall, J W A Smit, J A Romijn, et al. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 231 - 238. [Abstract] [Full Text] [PDF]

				A. Colao, D. Ferone, P. Marzullo, and G. Lombardi Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management Endocr. Rev., February 1, 2004; 25(1): 102 - 152. [Abstract] [Full Text] [PDF]

				R. Attanasio, R. Baldelli, R. Pivonello, S. Grottoli, L. Bocca, V. Gasco, M. Giusti, G. Tamburrano, A. Colao, and R. Cozzi Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5258 - 5265. [Abstract] [Full Text] [PDF]

				P. U. Freda Somatostatin Analogs in Acromegaly J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018. [Full Text] [PDF]

				A. Colao, P. Marzullo, D. Ferone, L. Spinelli, A. Cuocolo, D. Bonaduce, M. Salvatore, V. Boerlin, I. Lancranjan, and G. Lombardi Cardiovascular Effects of Depot Long-Acting Somatostatin Analog Sandostatin LAR in Acromegaly J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3132 - 3140. [Abstract] [Full Text]

				P. Marzullo, A. Cuocolo, D. Ferone, R. Pivonello, M. Salvatore, G. Lombardi, and A. Colao Cardiac Effect of Thyrotoxicosis in Acromegaly J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1426 - 1432. [Abstract] [Full Text]